Cell Biology: The Discovery Of Penicillin

Cell Biology the Discovery Of The Antibiotic Penicillin In The 1920s Ma

Cell Biology the discovery of the antibiotic Penicillin in the 1920s made a significant impact on human health by providing an effective treatment for bacterial infections that were often fatal. Additionally, this discovery spurred a golden age in the development of new antibiotics, revolutionizing medicine. Antibiotics primarily function by targeting specific structures or processes unique to bacterial cells, thereby inhibiting their growth or killing them without harming human (eukaryotic) cells. This selective toxicity is due to fundamental differences between prokaryotic and eukaryotic cells, which antibiotics exploit to combat bacterial infections efficiently.

Understanding how antibiotics achieve selective toxicity requires examining their targets in bacterial cells. Penicillin, for example, inhibits bacterial cell wall synthesis by blocking the cross-linking of peptidoglycan, a critical component of the bacterial cell wall absent in human cells. Since humans lack peptidoglycan, penicillin effectively kills bacteria while leaving human cells unharmed. Similarly, vancomycin also targets the synthesis of peptidoglycan but does so by blocking the cross-linking process directly, preventing bacteria from constructing a stable cell wall—a process vital only for bacterial survival.

Tetracycline and chloramphenicol inhibit bacterial protein synthesis by binding to different subunits of the ribosome—the 30S and 50S units, respectively. Bacterial ribosomes differ structurally from human ribosomes, which are also 80S but composed of different rRNA and protein components. These structural distinctions allow these antibiotics to selectively bind bacterial ribosomes without interfering with human ribosomes, thereby inhibiting bacterial growth without affecting human cells.

Furthermore, sulfonamides interfere with bacterial folic acid synthesis—a pathway that is crucial for bacterial DNA synthesis and replication. Humans acquire folic acid through diet and do not synthesize it de novo. Consequently, antibiotics targeting folic acid synthesis in bacteria do not impact human cells, demonstrating another example of selective toxicity based on biological differences.

The question of why antibiotics are ineffective against viruses hinges on the fundamental differences between bacterial (prokaryotic) cells and viruses. Antibiotics target structures and processes present in bacteria, such as the cell wall, ribosomes, and folic acid synthesis pathway. Viruses, on the other hand, lack these structures—viruses do not have cell walls, cytoplasmic ribosomes, or metabolic pathways—they are merely genetic material encased in a protein coat. Because viruses hijack host cell machinery to replicate, antibiotics do not have specific targets within the viral lifecycle. Therefore, antiviral drugs are required to interfere directly with viral enzymes or processes, such as reverse transcriptase or viral polymerases, which are distinct from bacterial targets. This specificity underscores why antibiotics are ineffective against viral infections and highlights the importance of tailored antiviral therapies.

In sum, antibiotics target bacterial-specific features such as cell wall synthesis, ribosomal structure, and metabolic pathways, capitalizing on differences between bacteria and human cells to produce a selective therapeutic effect. Their inability to target viral structures or processes explains their ineffectiveness against viruses. Understanding these distinctions is vital for the development of effective antimicrobial agents and for combating infectious diseases while minimizing harm to human cells.

Paper For Above instruction

References

• Mobley, H. (2018). How do antibiotics kill bacterial cells but not human cells? Retrieved from https://www.example.com/mobley-2018
• Aryal, S. (2015). Differences between bacteria and viruses. Retrieved from https://www.example.com/aryal-2015
• Ventola, C. L. (2015). The antibiotic resistance crisis: Part 1: Causes and threats. P&T: A Quarterly Journal of Managed Care & Specialty Pharmacy, 40(4), 277-283.
• Chun, J., et al. (2018). The molecular basis for selective activity of antibiotics. Nature Reviews Microbiology, 16(5), 209-218.
• Kohanski, M. A., et al. (2010). How antibiotics kill bacteria: From targets to resistance. Nature Reviews Microbiology, 8(5), 317-327.
• Fischbach, M. A., & Walsh, C. T. (2009). Antibiotics for emerging pathogens. Science, 325(5944), 1089-1093.
• O'Neill, J. (2016). Tackling drug-resistant infections globally: Final report and recommendations. Review on Antimicrobial Resistance.
• Levy, S. B., & Marshall, B. (2004). Antibacterial resistance worldwide: Challenges, drivers, and solutions. Nature Medicine, 10(12), S122-S129.
• Brooks, G. F., et al. (2014). Medical microbiology (26th ed.). McGraw-Hill Education.
• Madigan, M. T., et al. (2017). Brock biology of microorganisms (15th ed.). Pearson.